India Approves Gennova Biopharmaceuticals’ mRNA COVID-19 Booster Vaccine Targeting Omicron Variant

India’s Gennova Biopharmaceuticals has received emergency use authorization from the Drugs Controller General of India (DCGI) for its mRNA COVID-19 booster vaccine, GEMCOVAC-OM, designed specifically against the Omicron variant. This promising vaccine aims to address the challenges posed by the Omicron variant and prevent future waves of the pandemic.

Addressing the Omicron Variant Challenge

The emergence of the Omicron variant and the limited efficacy of existing vaccines against it have necessitated the development of a booster dose. GEMCOVAC-OM is specifically designed to counter the Omicron variant and bridge the gap left by current vaccines.

Launch and Availability

GEMCOVAC-OM is expected to be launched in the next few weeks, starting in New Delhi. The cost and availability details will be announced during the launch. Currently, 1.2 million booster doses are available at the Central Drugs Laboratory (CDL) in Kasauli, which oversees regulations for domestically produced vaccines.

Safety and Administration

GEMCOVAC-OM can be safely administered as a booster dose to individuals aged 18 and older who have received two doses of Covaxin or Covishield. The vaccine is stable at 2-8 °C and is administered intradermally using the Tropis device developed by PharmaJet, USA.

Indigenous Platform Technology Development

The Department of Biotechnology (DBT) has played a pivotal role in establishing Gennova’s mRNA-based vaccine manufacturing. The platform technology, developed through the Mission COVID Suraksha initiative, has enabled the creation of an Omicron-specific booster vaccine.

The Future of mRNA Vaccines

Gennova Biopharmaceuticals becomes the first Indian company and the third globally, following Moderna and Pfizer, to develop an mRNA COVID-19 booster vaccine against the highly transmissible Omicron variant. Gennova’s mRNA platform provides a rapid response capability for developing vaccines against future variants of concern.

About the Department of Biotechnology

The Department of Biotechnology, under the Ministry of Science and Technology, oversees the development and commercialization of modern biology and biotechnology in India. It is headquartered in New Delhi, with Jitendra Singh serving as the Minister of Science and Technology.

Gennova Biopharmaceuticals’ mRNA COVID-19 Booster Vaccine – FAQs

Q1: What is GEMCOVAC-OM?

Ans: Gennova Biopharmaceuticals created the mRNA COVID-19 booster vaccine GEMCOVAC-OM especially to combat the Omicron type of SARS-CoV2.

Q2: What role has the Department of Biotechnology (DBT) played in the development of GEMCOVAC-OM?

Ans: The DBT was instrumental in setting up Gennova’s mRNA-based vaccine production, and it supported the clinical development and scale-up of the vaccine under the Mission COVID Suraksha project.

Q3: What is the Department of Biotechnology (DBT)?

Ans: India’s Ministry of Science and Technology oversees the DBT, a government department. The emphasis is on the nation’s advancement and commercialization of contemporary biology and biotechnology.


  • Pritipalit

    Priti Palit, an accomplished edtech writer, boasts a wealth of experience in preparing candidates for multiple government exams. With a passion for education and a keen eye for detail, she has contributed significantly to the field of online learning. Priti's expertise and dedication continue to empower aspiring individuals in their pursuit of success in government examinations.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top